Wojciech Garczorz

Dr. Wojciech Garczorz

Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Poland
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MDMieczysław Dutka
Mieczysław Dutka
RBRafal Bobinski
Rafal Bobinski
TFTomasz Francuz
Tomasz Francuz
WGWojciech Garczorz
Wojciech Garczorz
KZKarolina Zimmer
Karolina Zimmer
MHMaciej B. Hajduga
Maciej B. Hajduga
A new group of antidiabetic drugs, sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors), have recently been shown to have anticancer effects and their expression has been confirmed in many cancer cell lines. Given the metabolic reprogramming of these cells in a glucose-based model, the ability of SGLT-2 inhibitors to block the glucose uptake by cancer cells appears to be an attractive therapeutic approach. In addition to tumour cells, SGLT-2s are only found in the proximal tubules in the kidneys. Furthermore, as numerous clinical trials have shown, the use of SGLT-2 inhibitors is well-tolerated and safe in patients with diabetes and/or heart failure. In vitro cell culture studies and preclinical in vivo studies have confirmed that SGLT-2 inhibitors exhibit antiproliferative effects on certain types of cancer. However, the mechanisms of this action remain unclear. Even in those tumour cell types in which SGLT-2 is present, there is sometimes an SGLT-2-independent mechanism of anticancer action of this group of drugs. This article presents the current state of knowledge of the potential mechanisms of the anticancer action of SGLT-2 inhibitors and their possible future application in clinical oncology.

1 November 2017 in Endocrine Connections
Verified
Journal Article
Open access
PDF file
AKAgnieszka Kosowska
Agnieszka Kosowska
Enrique J. Gallego-GallegoEnrique J. Gallego-Gallego
Enrique J. Gallego-Gallego
WGWojciech Garczorz
Wojciech Garczorz
AKAgnieszka Kłych-Ratuszny
Agnieszka Kłych-Ratuszny
MAMohammad Reza F Aghdam
Mohammad Reza F Aghdam
TFTomasz Francuz
Tomasz Francuz
Diabetes and cancer are prevalent diseases whose incidence is increasing globally. Diabetic women have a moderate risk increase in ovarian cancer, suggested to be due to an interaction between these two disorders. Furthermore, patients manifesting both diseases have associated worse prognosis, reduced survival and shorter relapse-free survival. According to current recommendations, incretin drugs such as Exenatide, a synthetic analog of Exendin-4, and Liraglutide are used as therapy for the type 2 diabetes (T2D). We studied the effects of GLP-1 and Exendin-4 on migration, apoptosis and metalloproteinase production in two human ovarian cancer cells (SKOV-3 and CAOV-3). Exendin-4 inhibited migration and promoted apoptosis through caspase 3/7 activation. Exendin-4 also modulated the expression of key metalloproteinases (MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2). Vascular endothelial cells, which contribute to the formation and progression of metastasis, were also analyzed. TNF-α-stimulated endothelial cells from iliac artery after Exendin-4 treatment showed reduced production of adhesion molecules (ICAM-1 and VCAM-1). Additionally, incretin treatment inhibited activation of apoptosis in TNF-α-stimulated endothelial cells. In the same experiment, MMPs (MMP-1 and MMP-9), which are relevant for tumor development, were also reduced. Our study demonstrated that incretin drugs may reduce cancer cell proliferation and dissemination potential, hence limiting the risk of metastasis in epithelial ovarian cancer.

28 December 2017 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
WGWojciech Garczorz
Wojciech Garczorz
Enrique J. Gallego-GallegoEnrique J. Gallego-Gallego
Enrique J. Gallego-Gallego
AKAgnieszka Kosowska
Agnieszka Kosowska
AKAgnieszka Kłych‐Ratuszny
Agnieszka Kłych‐Ratuszny
MWMichał Woźniak
Michał Woźniak
TFTomasz Francuz
Tomasz Francuz
Summary: Introduction: Cardiovascular disease is the main cause of mortality and morbidity in the industrialized world. Incretin‐mimetic compounds such as exenatide are currently used in the treatment of type 2 diabetes.Aims: We investigated the effects of incretin drugs on apoptosis, adhesion molecule expression, and concentration of extracellular matrix (ECM) metalloproteinases under inflammatory conditions within the context of atherosclerotic plaque formation of both human coronary artery endothelial cells (hCAECs) and human aortic endothelial cells (hAoECs). TNF‐α‐stimulated hCAEC and hAoEC were treated with exenatide (1 and 10 nmol/L) and GLP‐1 (10 and 100 nmol/L) then evaluated for caspase 3/7 activity and assayed for protein levels of adhesion molecules sICAM‐1, sVCAM‐1, and P‐selectin. Concentrations of matrix metalloproteinases (MMPs) MMP‐1, MMP‐2, MMP‐9, and their inhibitors—tissue inhibitor of metalloproteinases (TIMPs), TIMP‐1, TIMP‐2 were also measured to evaluate the effects on extracellular matrix turnover within an inflammatory environment. Intracellular signaling pathways were evaluated via transfection of endothelial cells with a GFP vector under the NF‐κB promoter.Results: Our experimental data suggest that GLP‐1 receptor (GLP‐1R) agonists downregulate activation of NF‐κB and adhesion molecules ICAM and VCAM, but not P‐selectin, in both endothelial cell lines. Exendin‐4 and GLP‐1 modulate the expression of MMPs and TIMPs, with statistically significant effects observed at high concentrations of both incretins. Expressive modulation may be mediated by NF‐κB as observed by activation of the vector when stimulated under inflammatory conditions.Conclusion: These findings indicate that GLP‐1 analogs have anti‐inflammatory properties in endothelial cells that may play an important role in preventing atherosclerosis.

1 July 2013 in Pharmacological Reports
Verified
Journal Article
Closed access
MDMariola Dorecka
Mariola Dorecka
KSKrzysztof Siemianowicz
Krzysztof Siemianowicz
TFTomasz Francuz
Tomasz Francuz
WGWojciech Garczorz
Wojciech Garczorz
ACAgnieszka Chyra
Agnieszka Chyra
WRWanda Romaniuk
Wanda Romaniuk

1 February 2018 in Pharmacological Reports
Verified
Journal Article
Closed access
Enrique J. Gallego-GallegoEnrique J. Gallego-Gallego
Enrique J. Gallego-Gallego
AKAgnieszka Klych-Ratuszny
Agnieszka Klych-Ratuszny
AKAgnieszka Kosowska
Agnieszka Kosowska
WGWojciech Garczorz
Wojciech Garczorz
MAMohammad Reza F. Aghdam
Mohammad Reza F. Aghdam
TFTomasz Francuz
Tomasz Francuz

Verified
Journal Article
Open access
PDF file
AKAgnieszka Kosowska
Agnieszka Kosowska
WGWojciech Garczorz
Wojciech Garczorz
AKAgnieszka Kłych-Ratuszny
Agnieszka Kłych-Ratuszny
MAMohammad Reza F. Aghdam
Mohammad Reza F. Aghdam
MKMałgorzata Kimsa-Furdzik
Małgorzata Kimsa-Furdzik
TFTomasz Francuz
Tomasz Francuz
The strong association between diabetes mellitus type 2 and cancer is observed. The incidence of both diseases is increasing globally due to the interaction between them. Recent studies suggest that there is also an association between cancer incidence and anti-diabetic medications. An inhibitor of dipeptidyl-peptidase 4 (DPP-4), sitagliptin, is used in diabetes treatment. We examined the influence of sitagliptin alone or in combination with a cytostatic drug (paclitaxel) on the development of epithelial ovarian cancer cells and the process of metastasis. We examined migration, invasiveness, apoptosis, and metalloproteinases (MMPs) and their inhibitors’ (TIMPs) production in two human ovarian cancer cell lines. Sitagliptin induced apoptosis by caspase 3/7 activation in paclitaxel-treated SKOV-3 and OVCAR-3 cells. Sitagliptin maintained paclitaxel influence on ERK and Akt signaling pathways. Sitagliptin additionally reduced migration and invasiveness of SKOV-3 cells. There were distinct differences of metalloproteinases production in sitagliptin-stimulated ovarian cancer cells in both cell lines, despite their identical histological classification. Only the SKOV-3 cell line expressed MMPs and TIMPs. SKOV-3 cells co-treated with sitagliptin and paclitaxel decreased concentrations of MMP-1, MMP-2, MMP-7, MMP-10, TIMP-1, TIMP-2. The obtained data showed that sitagliptin used with paclitaxel may be considered as a possibility of pharmacological modulation of intracellular transmission pathways to improve the response to chemotherapy.